What are the most common mistakes with B7-33?
The most common B7-33 mistakes are treating community-vendor B7-33 as research grade clinical material; running it without published human safety data; stacking it with anything else. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for B7-33 is limited.
Common B7-33 mistakes
- Treating community-vendor B7-33 as research grade clinical material
- Running it without published human safety data
- Stacking it with anything else
References
- B7-33, single-chain peptide derivative of relaxin retains anti-fibrotic activity without hemodynamic effects — Hossain MA et al., Chem Sci, 2016
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin) — Marshall SA, O'Sullivan K, Ng HH, et al., European Journal of Pharmacology, 2017
- Single chain peptide agonists of relaxin receptors — Praveen P, Kocan M, Valkovic A, et al., Molecular and Cellular Endocrinology, 2019
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on B7-33
Last updated 2026-06-15.